Merck And The 'Strange Business' Of Antibiotics

Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.

Merck VP Joan Butterton
Joan Butterton oversees antibiotic development at Merck. • Source: Merck & Co. Inc.

Having one of the industry's largest portfolios of anti-infective drugs allows Merck & Co. Inc. to weather the various storms within this sector of the biopharmaceutical industry, where there is a major need for new medicines to combat antimicrobial resistance (AMR), but where stewardship is required to make sure overuse doesn't worsen the AMR crisis.

Merck has a long history of developing antibiotics and antifungals, and has stuck with the challenging therapeutic area because of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category